Basic Information
LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML
INJECTION, SOLUTION (RADIOPHARMACEUTICAL)
Regulatory Information
SIN15947P
June 1, 2020
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XV10XX04
Company Information
NOVARTIS (SINGAPORE) PTE LTD
NOVARTIS (SINGAPORE) PTE LTD
Active Ingredients
Strength: 370 Mbq/ml
Detailed Information
Contraindications
**5 Contraindications** Established or suspected pregnancy or when pregnancy has not been excluded (see section Pregnancy, lactation, females and males of reproductive potential – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Severe renal impairment (creatinine clearance < 30 mL/min).
Indication Information
**3 Indications** Lutathera® is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.